Bio-Rad Laboratories Financial Statements
NYSE: BIOIndustrialsBiotechnology: Laboratory Analytical InstrumentsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
After hours: 366.16 -0.02%
Bio-Rad Laboratories revenue and earnings
In fiscal 2025, Bio-Rad Laboratories generated $2.58 billion in revenue, up 0.7% from fiscal 2024. Net income was $759.9 million, for a net margin of 29.4% versus a median of -23.9% in the prior 5 years. Gross margin was 51.9% (down from 53.7%) and operating margin 1.8%.
Diluted earnings per share came in at $27.85. Over the last 5 fiscal years, BIO's revenue has grown at a 0.3% compound annual rate.
Summary generated from market data by MetaCap's automated system. Methodology
Bio-Rad Laboratories income statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.58B | 2.57B | 2.67B | 2.80B | 2.92B | 2.55B | 2.31B | 2.29B | 2.16B | 2.07B |
| Revenue growth (YoY) | +0.65% | -3.92% | -4.67% | -4.12% | +14.81% | +10.12% | +0.97% | +5.98% | +4.45% | +2.41% |
| Cost of Revenue | 1.24B | 1.19B | 1.24B | 1.23B | 1.28B | 1.11B | 1.05B | 1.07B | 972.45M | 929.74M |
| Gross Profit | 1.34B | 1.38B | 1.43B | 1.57B | 1.64B | 1.44B | 1.26B | 1.22B | 1.19B | 1.14B |
| Operating Expenses | 1.29B | 1.11B | 1.09B | 1.08B | 1.14B | 1.02B | 1.03B | 1.33B | 1.07B | 1.08B |
| Research & Development | 275.60M | 295.90M | 247.40M | 256.90M | 260.64M | 217.76M | 202.71M | 199.20M | 250.16M | 205.71M |
| Selling, General & Admin | 844.30M | 814.00M | 841.70M | 827.80M | 877.12M | 798.80M | 824.63M | 834.78M | 806.79M | 814.70M |
| Operating Income | 47.20M | 269.00M | 337.80M | 482.60M | 500.34M | 421.33M | 229.66M | -103.34M | 119.25M | 55.72M |
| Interest Expense | 49.00M | 48.90M | 49.40M | 38.10M | 1.55M | 21.86M | 23.42M | 23.96M | 23.01M | 23.38M |
| Other Income (Expense) | 90.30M | 90.30M | 106.50M | 44.70M | 26.77M | 24.49M | 26.09M | 36.59M | 10.70M | 0 |
| Pretax Income | 995.50M | -2.34B | -850.10M | -4.70B | 5.45B | 4.92B | 2.26B | 512.66M | 97.81M | 41.56M |
| Income Tax | 235.60M | -498.30M | -212.80M | -1.08B | 1.19B | 1.10B | 502.41M | 147.04M | -24.44M | 15.56M |
| Net Income | 759.90M | -1.84B | -637.30M | -3.63B | 4.25B | 3.81B | 1.76B | 365.61M | 122.25M | 26.00M |
| Net Income growth (YoY) | — | — | — | -185.27% | +11.54% | +116.88% | +381.02% | +199.07% | +370.19% | -76.20% |
| EPS (Basic) | 27.87 | -65.36 | -21.82 | -121.79 | 142.61 | 128.13 | 58.93 | 12.25 | 4.12 | 0.88 |
| EPS (Diluted) | 27.85 | -65.36 | -21.82 | -121.79 | 140.83 | 126.47 | 58.27 | 12.10 | 4.07 | 0.88 |
| Shares Outstanding (Basic) | 27.26M | 28.21M | 29.21M | 29.79M | 29.83M | 29.77M | 29.84M | 29.84M | 29.66M | 29.44M |
| Shares Outstanding (Diluted) | 27.28M | 28.21M | 29.21M | 29.79M | 30.21M | 30.16M | 30.18M | 30.23M | 30.03M | 29.65M |
| EBITDA | 212.60M | 420.60M | 483.70M | 619.90M | 637.94M | 559.93M | 363.86M | 34.76M | 267.95M | 198.62M |
| Gross Margin | 51.87% | 53.73% | 53.42% | 55.93% | 56.05% | 56.49% | 54.38% | 53.43% | 54.98% | 55.04% |
| Operating Margin | 1.83% | 10.48% | 12.65% | 17.22% | 17.12% | 16.55% | 9.93% | -4.51% | 5.52% | 2.69% |
| Net Margin | 29.42% | -71.86% | -23.86% | -129.45% | 145.57% | 149.84% | 76.08% | 15.97% | 5.66% | 126.00% |
This table shows 10 annual periods of Bio-Rad Laboratories's income statement, from FY 2025 back to FY 2016, across 20 line items including revenue, cost of revenue, gross profit. Values in USD; B = billions, M = millions. Fiscal periods follow BIO's reporting calendar. What is a income statement?